XBiotech Completes Enrollment in Global Phase I/II Study for its True Human(TM) Antibody Treatment for Serious Staphylococcus aureus Infections
XBiotech Inc. (NASDAQ:XBIT), developer of True Human(TM) therapeutic antibodies, today announced that enrollment has bee…